After experiencing a bumper harvest in 2024, the USA ETF may encounter setbacks this year.

The USA Exchange Traded Fund (ETF) received a record inflow of $1.1 trillion in 2024, but entering 2025, rapid growth may face more obstacles.

Zhitong FinanceJan 2 20:49

Regeneron Pharmaceuticals' (NASDAQ:REGN) Investors Will Be Pleased With Their Decent 89% Return Over the Last Five Years

Yahoo FinanceDec 31, 2024 20:00

Here Are Morgan Stanley's Key Oncology Catalysts for 2025

Seeking AlphaDec 28, 2024 23:31

Regeneron Pharmaceuticals (NASDAQ:REGN) Could Easily Take On More Debt

Simply Wall StDec 24, 2024 23:02

The USA FDA has revoked the emergency use authorization for four COVID-19 antibody drugs.

On December 24, Gelonghui reported that the USA Food and Drug Administration (FDA) has revoked the emergency use authorization for four COVID-19 antibody drugs, including Eli Lilly and Co's bebtelovimab, AstraZeneca's Evusheld, GlaxoSmithKline's sotrovimab, and Regeneron's REGEN-COV. The FDA stated in a letter earlier this month that the shelf life of these drugs has expired, and due to the spread of non-susceptible variants, they have not been authorized for patient use for more than a year. According to the FDA, the four companies mentioned above do not intend to continue providing the relevant products in the USA and will notify customers and suppliers.

Gelonghui FinanceDec 24, 2024 14:58

Express News | US FDA: Revoked Emergency Use Authorization for Regeneron's Regen-Cov as of Dec 13 - Website

BreakingsDec 24, 2024 01:12